Shuying Qiu, Jianping Zhang, Zhuo Wang, Hui Lan, Jili Hou, Nan Zhang, Xian Wang, Haiqi Lu
Biochimica et biophysica acta. Reviews on cancer 2023 JulThe development of new antitumor drugs depends mainly upon targeting tumor cells precisely. Trophoblast surface antigen 2 (Trop-2) is a type I transmembrane glycoprotein involved in Ca2+ signaling in tumor cells. It is highly expressed in various tumor tissues than in normal tissues and represents a novel and promising molecular target for caner targeted therapy. Up to now, the mechanisms and functions associated with Trop-2 have been extensively studied in a variety of solid tumors. According to these findings, Trop-2 plays an important role in cell proliferation, apoptosis, cell adhesion, epithelial-mesenchymal transition, as well as tumorigenesis and tumor progression. In addition, Trop-2 related drugs are also being developed widely. There are a number of Trop-2 related ADC drugs that have demonstrated potent antitumor activity and are currently been studied, such as Sacituzumab Govitecan (SG) and Datopotamab Deruxtecan (Dato-Dxd). In this study, we reviewed the progress of Trop-2 research in solid tumors. We also sorted out the composition and rationale of Trop-2 related drugs and summarized the related clinical trials. Finally, we discussed the current status of Trop-2 research and expanded our perspectives on its future research directions. Importantly, we found that Trop-2 targeted ADCs have great potential for combination with other antitumor therapies. Trop-2 targeted ADCs can reprogramme tumor microenvironment through multiple signaling pathways, ultimately activating antitumor immunity. Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Shuying Qiu, Jianping Zhang, Zhuo Wang, Hui Lan, Jili Hou, Nan Zhang, Xian Wang, Haiqi Lu. Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochimica et biophysica acta. Reviews on cancer. 2023 Jul;1878(4):188902
PMID: 37121444
View Full Text